# BLLN earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/BLLN) · [Earnings tab](https://www.lopjlb.com/stock/BLLN?tab=earnings) Updated: 2026-10-06T05:50:45 Quarters analyzed: 4 ## Cross-quarter narrative Across the four earnings calls BLLN’s core story shifted from explosive top‑line expansion and milestone delivery in Q3 2025 to a more nuanced picture of sustained growth tempered by execution risks. Revenue growth remained double‑digit (117% YoY in Q3 2025, 84% in Q1 2026, 64% in Q2 2026) but the rate decelerated, while gross margins hovered around 70% with a brief peak at 73% before a modest dip. The company continued to roll out new products—Unity Confirm, fetal antigen screens, and multiple oncology assays—while expanding payer contracts such as the Anthem network. However, recurring concerns grew around health‑system integration timelines, pending Medicare MolDX coverage for NorthStar Response, and the exclusion of true‑up revenue from guidance, all of which introduced uncertainty. Capital remained strong, supporting sales force expansion and R&D, yet the timing of health‑payer claim recoveries and the build‑out of an oncology lab added to the risk profile. Management’s tone stayed generally positive, but guidance uncertainty rose, reflecting the mounting execution and reimbursement challenges. ## Latest CallCard · Q2 BLLN reported 64% YoY revenue growth, 70.5% gross margin and new product launches while maintaining guidance amid uncertainty over pending claims and MolDX coverage timing. **Guidance:** maintained — Management kept guidance unchanged pending clarity on claim recoveries and coverage timing. **Tone:** mgmt 0.8 · Q&A pressure 0.6 · divergence 0.4 Prepared remarks highlighted high growth, excellent margins, positive operating income and cash flow, portraying an upbeat outlook. ### Demand visibility Strong demand growth across prenatal and oncology Test volume grew 35% YoY to ~196k; prenatal revenue +56% YoY, oncology revenue +176% YoY, driving 64% revenue increase. ### Margins / costs Margins above 70% with room for expansion Gross margin 70.5% (up 5 pts YoY); ASP up 21% YoY; COGS per test fell to $101 from $152, though mix shift to oncology raises overall COGS. ### Capital allocation Investing in commercial scale, R&D and new oncology lab Added ~70 sales reps, signed lease for 62k‑sq‑ft oncology production lab (delivery 2027), expanded Unity Fetal Antigen Screen, updated NorthStar panels, and accelerated Epic Aura integration. ### Milestones - **UnityConfirm launch** [delivered]: Launched May 28; >50% of eligible high‑risk patients ordering. - **UNITY Fetal Antigen Screen expansion** [on_track]: Expanding panel to 130 genes on Aug 17, largest market panel. - **North Star response study publication** [delivered]: June 24 peer‑reviewed study supporting MolDX coverage. - **Tumor‑naive MRD launch** [on_track]: Targeted launch by year‑end. - **NorthStar Select panel expansion** [on_track]: Expanding to 102 genes on Sep 1, adding MTAP loss detection. - **NorthStar Origin tissue‑of‑origin add‑on** [new]: Launching with 91% accuracy for cancer of unknown primary. - **Epic Aura integration** [delivered]: Integrated in under 5 months; first health‑system integration completed in 2 weeks. - **Oncology production lab build** [on_track]: Lease signed; build expected completion end of 2027 for 5k tests/day capacity. ### Fears / risks - **Reimbursement risk**: MolDX Medicare coverage for North Star response is pending and expected by year‑end. - **Claims processing risk**: $10M of health‑payer claims are held; timing and amount of recovery are uncertain. - **Integration risk**: Each health system may require 2‑4 quarters to activate Epic Aura integration despite fast lab setup. - **Margin dilution risk**: Accelerated oncology growth could temporarily push gross margins below 70%. - **True‑up exclusion risk**: Guidance excludes true‑up revenue, creating potential variance between guidance and actual results. - **Seasonality risk**: Larger scale may increase seasonal impact on revenue, which is not currently modeled. ### Key quotes > “We delivered another quarter with high growth, excellent margins and positive operating income and cash flow.” > “Our gross margins stayed remarkably consistent in the past few quarters, despite an increase in COGS per test, as our mix shifts toward a higher proportion of oncology tests.” > “We are launching new products both in prenatal and oncology, and we have published data that we believe will support MolDX coverage for North Star response.” > “Our first integrations have been, you know, 2 to 4 weeks, which is a record time even for, you know, these individual health system integrations.” ## Quarter one-liners - **2026 Q2:** BLLN reported 64% YoY revenue growth, 70.5% gross margin and new product launches while maintaining guidance amid uncertainty over pending claims and MolDX coverage timing. - **2026 Q1:** BLLN Q1 2026: 84% revenue growth to $108.4M, 73% gross margins, 16% GAAP operating margin, launched Unity Confirm fetal cell test, added Anthem contract (300M lives), oncology revenue up ~5x to $10.7M. - **2025 Q4:** — - **2025 Q3:** BLLN posted 117% revenue growth, 70% gross margin and GAAP operating profit in Q3 2025, while highlighting strong test volume expansion, ongoing EMR integration and upcoming Medicare coverage milestones. ## Theme arcs - **Revenue growth rate** (deteriorating): YoY growth slowed from 117% to 64% across calls - **Gross margin** (stable): Margins stayed near 70% with a brief rise to 73% then slight dip - **Oncology product expansion** (improving): Multiple oncology launches and pipeline progress reported - **Health‑system/EMR integration** (deteriorating): Integration timelines remain 2‑4 quarters, risk of delayed volume capture - **Medicare/MolDX reimbursement risk** (deteriorating): Coverage for NorthStar Response remains pending across calls - **True‑up revenue exclusion** (stable): Guidance consistently excludes true‑up revenue, creating variance risk - **Competitive prenatal landscape** (stable): Competitor launches noted as ongoing concern - **Capital position and discipline** (stable): Strong cash balance maintained while funding sales and R&D ## Guidance path 2025 Q3:maintained → 2025 Q4:vague → 2026 Q1:raised → 2026 Q2:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/BLLN`